Search

Displaying results 1181 - 1190 of 10000 in total
  1. Drug

    Etelcalcetide

    go.drugbank.com/drugs/DB12865
    ApprovedInvestigational

    Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. … Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis.

  2. Drug

    Phosphatidyl serine

    go.drugbank.com/drugs/DB00144
    ApprovedNutraceutical

    PS has been investigated in a small number of double-blind placebo trials and has been shown to increase memory performance in the elderly. … PS has been shown to slow cognitive decline in animal models.

    Mixtures: Enl
  3. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. … It contains 6 N-linked oligosaccharide modification sites.

  4. Drug

    Vutrisiran

    go.drugbank.com/drugs/DB16699
    ApprovedInvestigational

    [L34490,L42065] Vutrisiran is commercially available as a conjugate of N-acetylgalactosamine (GalNAc), a residue that enables the delivery of siRNA to hepatocytes. … [A249010] Vutrisiran was approved by the FDA in June 2022.

  5. Drug

    Anakinra

    go.drugbank.com/drugs/DB00026
    ApprovedInvestigational

    On November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. … It was later approved for the treatment of NOMID and DIRA on December 21, 2012, and December 18, 2020, respectively.

  6. Drug

    Golodirsen

    go.drugbank.com/drugs/DB15593
    ApprovedInvestigational

    Continued approval of this drug will depend on the results of clinical trials that confirm its clinical benefit. … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Salmeterol

    go.drugbank.com/drugs/DB00938
    ApprovedInvestigational

    [A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542] … [A190459] Salmeterol was first described in the literature in 1988.[A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.

    Mixtures: SALFLUTIN 50/100UG 60 ED, SALFLUTIN 50/250UG 60 ED
  8. Drug

    Baloxavir marboxil

    go.drugbank.com/drugs/DB13997
    ApprovedInvestigational

    [L4779] It was also approved by the European Commission on January 7, 2021.[L45241] … [A251760] Baloxavir marboxil was first globally approved in Japan in February 2018,[A39895] followed by the US approval in October, 2018.

  9. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). … Linerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT).

  10. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. … Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor.